· 1d · on MSN
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
· 1d
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
· 1d
Johnson & Johnson: Q4 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2 per share. The world's biggest maker of health care products posted revenue of $22.52 billion in the period,
· 18h · on MSN
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
· 1d · on MSN
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
· 1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
Some results have been hidden because they may be inaccessible to you
Show inaccessible results